LH - Laboratory Corporation of America Holdings

NYSE - NYSE Delayed Price. Currency in USD
179.74
-0.90 (-0.50%)
At close: 4:00PM EDT

179.74 0.00 (0.00%)
After hours: 5:08PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close180.64
Open183.86
Bid179.74 x 1000
Ask179.75 x 1800
Day's Range179.11 - 185.82
52 Week Range98.02 - 196.36
Volume587,546
Avg. Volume1,242,703
Market Cap17.471B
Beta (5Y Monthly)1.07
PE Ratio (TTM)23.68
EPS (TTM)7.59
Earnings DateJul 23, 2020 - Jul 27, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 29, 1994
1y Target Est202.86
  • Top 6 Buys of Bernard Horn's Polaris Fund in the 1st Quarter
    GuruFocus.com

    Top 6 Buys of Bernard Horn's Polaris Fund in the 1st Quarter

    Fund’s buys include boost in Tyson and five new holdings Continue reading...

  • LabCorp Launches New COVID-19 Clinical Trial Site to Connect Patients With U.S. Research Trials
    Business Wire

    LabCorp Launches New COVID-19 Clinical Trial Site to Connect Patients With U.S. Research Trials

    LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that Covance, its drug development business, has created COVID-19 Clinical Trial Connect in the U.S., a site designed to help people access information about how to participate in COVID-19 research.

  • Laboratory Corp. of America Holdings (LH): Are Hedge Funds Right About This Stock?
    Insider Monkey

    Laboratory Corp. of America Holdings (LH): Are Hedge Funds Right About This Stock?

    In this article we will check out the progression of hedge fund sentiment towards Laboratory Corp. of America Holdings (NYSE:LH) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their […]

  • Coronavirus update: Novartis enters vaccine race as reopenings, testing efforts ramp up
    Yahoo Finance

    Coronavirus update: Novartis enters vaccine race as reopenings, testing efforts ramp up

    Pharmaceutical companies on Thursday continued their pursuit of a breakthrough in the fight against the coronavirus pandemic.

  • Reuters

    LabCorp ties up with software provider to expand virtual clinical trials

    Medable's modular software platform will help patients registered with LabCorp's drug development unit Covance to participate in decentralized clinical trials and facilitate remote data collection and engagement between patients, sites and clinical investigators. In recent months, clinical trial service providers have reported a spike in demand for virtual trials as pharmaceutical companies try to prevent the coronavirus outbreak from derailing their drug rollouts.

  • LabCorp Accelerates Adoption of Decentralized Clinical Trials, Expands Technology Ecosystem Through Alliance With Medable
    Business Wire

    LabCorp Accelerates Adoption of Decentralized Clinical Trials, Expands Technology Ecosystem Through Alliance With Medable

    LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that Covance, its drug development business, is expanding its technology ecosystem to accelerate the adoption of decentralized clinical trials, often referred to as hybrid and virtual clinical trials.

  • Quest Diagnostics rolls out return-to-work services
    Yahoo Finance

    Quest Diagnostics rolls out return-to-work services

    Quest Diagnostics is offering companies of all sizes a package of services that include on-site temperature checks, antibody or swab testing.

  • Richard Snow Buys Into Tyson and Reduces Dow in 1st Quarter
    GuruFocus.com

    Richard Snow Buys Into Tyson and Reduces Dow in 1st Quarter

    Guru's top buys and sells Continue reading...

  • Why Is Everyone Talking About LabCorp Stock?
    Motley Fool

    Why Is Everyone Talking About LabCorp Stock?

    Millions of tests for COVID-19 have been performed in the U.S., but experts and politicians continue to emphasize that increased testing for the coronavirus is essential for a safe reopening of the economy. With testing so much in the public discussion now, it's not surprising that leading medical testing companies are getting attention from investors, especially as new COVID-19 tests are being granted emergency use authorization every week. Laboratory Corporation of America (NYSE: LH), or LabCorp as it's known, is one of the biggest diagnostic testing companies in the country and has been in the headlines for coronavirus testing.

  • Reuters

    RPT-U.S. employers wary of coronavirus 'immunity' tests as they move to reopen

    U.S. employers have cooled to the idea of testing workers for possible immunity to the coronavirus as they prepare to reopen factories and other workplaces. Blood tests that check for antibodies to the new coronavirus have been touted by governments and some disease experts as a way to identify people who are less likely to fall ill or infect others. Italian automaker Ferrari NV has made antibody testing central to its “Back on Track” project to restarting factories.

  • REFILE-U.S. employers wary of coronavirus 'immunity' tests as they move to reopen
    Reuters

    REFILE-U.S. employers wary of coronavirus 'immunity' tests as they move to reopen

    U.S. employers have cooled to the idea of testing workers for possible immunity to the coronavirus as they prepare to reopen factories and other workplaces. Blood tests that check for antibodies to the new coronavirus have been touted by governments and some disease experts as a way to identify people who are less likely to fall ill or infect others. Italian automaker Ferrari NV has made antibody testing central to its “Back on Track” project to restarting factories.

  • LabCorp Launches COVID-19 Testing Service to Help Workers Get Back on the Job
    Motley Fool

    LabCorp Launches COVID-19 Testing Service to Help Workers Get Back on the Job

    Companies will be able to screen their employees for the coronavirus and test them for prior infections with SARS-CoV-2.

  • Coronavirus Vaccine Progress Accelerates
    Yahoo Finance

    Coronavirus Vaccine Progress Accelerates

    Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.

  • Coronavirus update: Soaring jobless claims jolt US debate over reopening states
    Yahoo Finance

    Coronavirus update: Soaring jobless claims jolt US debate over reopening states

    America’s growing ranks of jobless workers underscored the severe toll the coronavirus pandemic has taken on the world’s largest economy, while heightening a polarizing debate over restarting the U.S. economy.

  • Reuters

    LabCorp to make COVID-19 testing services available at workplaces

    The company said it would provide customized services for workplaces including temperature checks, COVID-19 test collection at offices, access to its at-home sample collection kit, antibody test, as well as flu vaccinations in the fall. LabCorp currently provides lab tests, antibody blood tests that can tell whether a person has ever been infected, as well as kits that allow people to mail in their own nasal swab samples, reducing risks of further transmission. LabCorp said its "return to work" offerings would also include wellness services such as biometric screening.

  • LabCorp Launches Return to Work Services for Employers
    Business Wire

    LabCorp Launches Return to Work Services for Employers

    LabCorp (NYSE: LH) announced today it is launching a new return to work service for employers. Many U.S. companies have asked for LabCorp’s assistance as they implement their return to work strategies for the summer and fall. To meet this urgent demand, LabCorp Employer Services provides customized return to work solutions using LabCorp’s trained medical staff for employee check-in health questionnaires, temperature screens, and COVID-19 test collection at the employer site or offsite. The service gives employers access to LabCorp’s COVID-19 testing solutions including its at-home collection test kit, its new fingerstick antibody blood test, and in the fall, flu vaccination services.

  • Coronavirus update: U.S. death toll tops 81,000; Trump defends administration’s record in testy exchange with reporters
    MarketWatch

    Coronavirus update: U.S. death toll tops 81,000; Trump defends administration’s record in testy exchange with reporters

    The U.S. death toll from the coronavirus that causes COVID-19 climbed above 81,000 on Tuesday, as President Donald Trump, defending his record on testing in the U.S., ended his White House news conference abruptly following an angry exchange with two reporters.

  • TheStreet.com

    LabCorp Expands Access to Covid-19 Home Test Kit

    LabCorp is expanding access to its Covid-19 home test kit beyond first responders and health-care workers to individuals nationwide who have symptoms.

  • Reuters

    LabCorp expands availability of at-home sample collection kit for COVID-19 testing

    LabCorp said on Tuesday it has now made available its at-home sample collection kit for COVID-19 testing to all individuals with symptoms and possible exposure to the virus, after having limited delivery to healthcare workers last month. The collection kit, launched in April with a list price of $119, comes with cotton swabs to collect nasal specimens, a biohazard specimen bag and a FedEx overnight shipping envelope to mail the samples to labs. LabCorp said it has over 200,000 at-home collection kits and was prepared to significantly expand capacity as required.

  • MarketWatch

    LabCorp's stock gains as at-home COVID-19 is expanded to the public

    Shares of Laboratory Corporation of America Holdings gained 2.1% in premarket trading on Tuesday after the test maker said it had expanded its at-home COVID-19 test to the general public. The at-home test, which received emergency use authorization from the Food and Drug Administration on April 20, was initially made available to frontline workers. Individuals who have been exposed to or have symptoms of COVID-19 can collect the sample at home using nasal swabs and then mail them to a lab. LabCorp's stock is down 0.2% year-to-date, while the S&P 500 has declined 9.3%.

  • LabCorp Significantly Expands Availability of Its COVID-19 At-Home Collection Test Kit
    Business Wire

    LabCorp Significantly Expands Availability of Its COVID-19 At-Home Collection Test Kit

    LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that its COVID-19 at-home collection test kit is now being offered to individuals nationwide who have symptoms consistent with COVID-19 infection and individuals without symptoms who may have been exposed to the virus. The test is available through the company’s Pixel by LabCorp™ online platform. Initially, the at-home collection test kits were made available in April to frontline healthcare workers and first responders and this latest move expands access in line with U.S. CDC guidelines.

  • Better Coronavirus Stock: Quest Diagnostics or LabCorp?
    Motley Fool

    Better Coronavirus Stock: Quest Diagnostics or LabCorp?

    No matter what happens, though, testing for COVID-19 will be important. Two of the largest diagnostics testing companies in the world, Quest Diagnostics (NYSE: DGX) and LabCorp (NYSE: LH), have stepped up in a major way to provide COVID-19 testing. Quest Diagnostics launched nationwide COVID-19 testing services in March.

  • U.S. FDA authorizes first at-home saliva test for COVID-19
    Reuters

    U.S. FDA authorizes first at-home saliva test for COVID-19

    The U.S. Food and Drug Administration said on Friday it has authorized the first diagnostic test for the new coronavirus that allows patients to collect saliva samples at-home. The decision is part of the FDA's efforts to expand testing capabilities for the fast-spreading virus, which has caused over 70,000 deaths in the United States. The saliva test kit was developed by RUCDR Infinite Biologics, a unit of Rutgers' Human Genetics Institute of New Jersey, and its collaborators, Spectrum Solutions and Accurate Diagnostic Labs.

  • Coronavirus update: U.S. death toll tops 71,000, as Trump backs off plan to wind down pandemic task force
    MarketWatch

    Coronavirus update: U.S. death toll tops 71,000, as Trump backs off plan to wind down pandemic task force

    The U.S. death toll from the coronavirus that causes COVID-19 rose above 71,000 on Wednesday, as President Donald Trump appeared to back off his announcement that he would phase out the government task force created to manage the pandemic